| All subjects |
56 |
100% |
64% |
29% |
39% |
75% |
| Gender |
|
|
|
|
|
|
| Males |
24 |
43% |
71% |
33% |
54% |
83% |
| Females |
32 |
57% |
59% |
25% |
28% |
69% |
| CKD stage |
|
|
|
|
|
|
| 0–2 |
25 |
45% |
68% |
36% |
44% |
76% |
| 3A |
14 |
25% |
50% |
21% |
43% |
71% |
| 3B |
10 |
18% |
80% |
20% |
40% |
80% |
| 4 |
4 |
7% |
25% |
50% |
0% |
50% |
| 5 |
3 |
5% |
100% |
0% |
33% |
100% |
| Tumor grade |
|
|
|
|
|
|
| Low |
6 |
11% |
67% |
50% |
17% |
67% |
| High |
50 |
89% |
64% |
26% |
42% |
76% |
| Tumor stage |
|
|
|
|
|
|
| Ta |
11 |
20% |
73% |
55% |
45% |
82% |
| T1 |
8 |
14% |
50% |
0% |
38% |
75% |
| T2 |
10 |
18% |
80% |
20% |
10% |
80% |
| T3 |
24 |
43% |
67% |
33% |
54% |
79% |
| T4 |
3 |
5% |
0% |
0% |
0% |
0% |
| Upper urinary tract tumor site |
|
|
|
|
|
|
| Lower ureter |
17 |
30% |
76% |
18% |
35% |
76% |
| Upper ureter |
1 |
2% |
100% |
0% |
0% |
100% |
| Ureterovesical junction |
2 |
4% |
0% |
0% |
0% |
0% |
| Lower ureter and upper ureter |
2 |
4% |
100% |
50% |
50% |
100% |
| Renal pelvis |
21 |
38% |
57% |
38% |
38% |
76% |
| Renal pelvis and lower ureter |
4 |
7% |
75% |
25% |
50% |
100% |
| Renal pelvis and upper ureter |
5 |
9% |
40% |
40% |
60% |
60% |
| Renal pelvis, lower ureter, upper ureter |
4 |
7% |
75% |
25% |
50% |
75% |
| Synchronous bladder cancer |
|
|
|
|
|
|
| Present |
21 |
38% |
52% |
29% |
33% |
62% |
| Absent |
35 |
63% |
71% |
29% |
43% |
83% |
| UTUC risk factors |
|
|
|
|
|
|
| Aristolactam-DNA adducts present |
54 |
96% |
65% |
30% |
39% |
74% |
| Smoking history |
10 |
18% |
70% |
30% |
60% |
70% |
| CKD, chronic kidney disease. |
|
|
|
|
|
|
